Keyphrases
Critically Ill Patients
100%
Acute Kidney Injury
100%
Eosinophils
66%
Randomized Controlled Trial
66%
Acute Exacerbation of COPD (AECOPD)
66%
Patient Data
66%
Procalcitonin
52%
Fluid Accumulation
47%
Ciprofloxacin
46%
Intensive Care Unit
40%
Intensive Care Patients
40%
Cefepime
40%
Systemic Corticosteroids
39%
Meropenem
36%
Open-label Trial
33%
Treatment Discontinuation
33%
Antibiotic Treatment
33%
Non-inferiority Trial
33%
Thrombocytopenia
33%
Hospitalized Patients
33%
Damage Signaling
33%
Corticosteroid-sparing
33%
Antibacterial Drugs
33%
Respiratory Infection
33%
Invasive Candidiasis
33%
Antimicrobial
33%
Treatment Limitation
33%
Piperacillin-tazobactam
33%
Nonrecovery
33%
Treatment Decisions
33%
Feasibility Trial
33%
Injury Biomarkers
33%
Endothelial Damage
33%
Hazard Ratio
27%
Prednisolone
24%
Fluid Overload
23%
Intensive Care Unit Patients
19%
Antibiotics
17%
Stable Phase
16%
Time-sensitive Communication
16%
Patient Caregivers
16%
Life-sustaining Treatment
16%
Patient Demand
16%
Quality of Life
16%
Informal Caregivers
16%
Disease Progression
16%
Palliation
16%
Disease Stage
16%
Medicine and Dentistry
Acute Kidney Injury
100%
Intensive Care Unit
70%
Biological Marker
67%
Intensive Care
66%
Chronic Obstructive Pulmonary Disease
66%
Eosinophil
66%
Procalcitonin
50%
Corticosteroid Therapy
41%
Acute Exacerbation of Chronic Obstructive Pulmonary Disease
41%
Fluid Balance
39%
Corticosteroid
34%
Disease Exacerbation
33%
Silo-Filler's Disease
33%
Open-Label Trial
33%
Noninferiority Trial
33%
Antibiotic Therapy
33%
Acute Respiratory Failure
33%
Respiratory Tract Infection
33%
Acute Respiratory Distress Syndrome
33%
Lung Injury
33%
Prednisolone
24%
Hypervolemia
23%
Diseases
23%
Life Sustaining Treatment
16%
Symptomatic Treatment
16%
Hazard Ratio
16%
Kidney Function
16%
Quality of Life
16%
Side Effect
15%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Kidney Failure
66%
Randomized Controlled Trial
66%
Ciprofloxacin
46%
Biological Marker
45%
Antiinfective Agent
40%
Cefuroxime
40%
Meropenem
36%
Chronic Obstructive Lung Disease
33%
Noninferiority Trial
33%
Corticosteroid
33%
Thrombocytopenia
33%
Surfactant Protein D
33%
Lung Injury
33%
Lung Disease
33%
Adult Respiratory Distress Syndrome
33%
Candidiasis
33%
Disease Exacerbation
33%
Hypervolemia
23%
Procalcitonin
23%
Diseases
16%
